Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has announced a board meeting scheduled for August 15, 2025, to discuss and approve the interim results for the first half of the year and consider the recommendation of an interim dividend. This meeting is significant as it may impact the company’s financial strategy and shareholder returns, reflecting its operational progress and market positioning.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands. It focuses on developing and commercializing innovative drugs, particularly in the areas of viral diseases, cancer, and fatty liver diseases.
Average Trading Volume: 5,765,709
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.26B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.